Skip to main content
Premium Trial:

Request an Annual Quote

ExonHit, BioMerieux Call off Colon Cancer Collaboration

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – ExonHit Therapeutics and BioMerieux are discontinuing their collaboration aimed at identifying biomarkers and developing tests for colon cancer, ExonHit announced today.

The decision reportedly comes on the heels of a recent review of scientific and clinical data from the colon cancer screening research program.

However, the companies plan to continue working together to find biomarkers and develop tests for early-stage prostate cancer.

"ExonHit's technology was able to produce a robust and reproducible test however, the final results from the colon cancer program did not reach the level of performance we were aiming to achieve," Loic Maurel, president of ExonHit's management board, said in a statement. "Therefore, we have decided together with BioMerieux to focus our efforts on the prostate cancer program."

As reported by GenomeWeb Daily News sister publication BioArray News reported last month, ExonHit is also developing microarray-based test for Alzheimer's disease that it hopes to launch in Europe early next year and in the US sometime in 2012.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.